...
首页> 外文期刊>Cancer gene therapy >Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability
【24h】

Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability

机译:沉默癌基因在宫颈癌干细胞中的表达抑制其细胞生长和自我更新能力

获取原文
           

摘要

Accumulating evidence supports the concept that cancer stem cells (CSCs) are responsible for tumor initiation and maintenance. They are also considered as an attractive target for advanced cancer therapy. Using a sphere culture method that favors the growth of self-renewal cells, we have isolated sphere-forming cells (SFCs) from cervical cancer cell lines HeLa and SiHa. HeLa-SFCs were resistant to multiple chemotherapeutic drugs and were more tumorigenic, as evidenced by the growth of tumors following injection of immunodeficient mice with 1 × 104 cells, compared with 1 × 106 parental HeLa cells required to grow tumors of similar size in the same time frame. These cells showed an expression pattern of CD44high/CD24low that resembles the CSC surface biomarker of breast cancer. We further demonstrated that HeLa-SFCs expressed a higher level (6.9-fold) of the human papillomavirus oncogene E6, compared with that of parental HeLa cells. Gene silencing of E6 with a lentiviral-short-hairpin RNA (shRNA) profoundly inhibited HeLa-SFC sphere formation and cell growth. The inhibition of cell growth was even greater than that for sphere formation after E6 silence, suggesting that the loss of self-renewing ability may be more important. We then measured the expression of self-renewal genes, transformation growth factor-beta (TGF-β) and leukemia-inhibitory factor (LIF), in shRNA-transduced HeLa-SFCs and found that expression of all three TGF-β isoforms was significantly downregulated while LIF remained unchanged. Expression of the Ras gene (a downstream component of TGF-β) was also markedly decreased, suggesting that the growth-inhibitory effect could be via the TGF-β pathway. The above data indicate RNA interference-based therapy may offer a new approach for CSC-targeted cancer therapy.
机译:越来越多的证据支持癌干细胞(CSC)负责肿瘤的发生和维持的概念。它们也被认为是晚期癌症治疗的有吸引力的靶标。使用有利于自我更新细胞生长的球形培养方法,我们从宫颈癌细胞系HeLa和SiHa中分离了球形形成细胞(SFC)。 HeLa-SFC对多种化学疗法药物具有抗药性,并且具有更高的致瘤性,如免疫缺陷小鼠注射1×104细胞后肿瘤的生长所证明的,相比之下,在相同大小的相同肿瘤中生长所需的1×106亲本HeLa细胞大体时间。这些细胞显示出CD44high / CD24low的表达模式,类似于乳腺癌的CSC表面生物标记。我们进一步证明,与亲代HeLa细胞相比,HeLa-SFCs表达更高水平(6.9倍)的人乳头瘤病毒癌基因E6。慢病毒-短发夹RNA(shRNA)对E6的基因沉默极大地抑制了HeLa-SFC球的形成和细胞生长。 E6沉默后,细胞生长的抑制作用甚至大于球形成的抑制作用,表明丧失自我更新能力可能更为重要。然后,我们测量了shRNA转导的HeLa-SFC中自我更新基因,转化生长因子-β(TGF-β)和白血病抑制因子(LIF)的表达,发现所有三种TGF-β亚型均显着表达下调,而LIF保持不变。 Ras基因(TGF-β的下游成分)的表达也显着降低,这表明生长抑制作用可能是通过TGF-β途径实现的。以上数据表明,基于RNA干扰的疗法可能为针对CSC的癌症疗法提供一种新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号